Palmatine alleviates LPS-induced acute lung injury via interfering the interaction of TAK1 and TAB1

Acute lung injury (ALI) is a severe clinical disease marked by uncontrolled inflammation response which lacks effective medicines. Accumulative evidence has indicated that macrophages are therapeutic targets for treating ALI because of its critical role in the inflammatory response. Palmatine (PAL), an isoquinoline alkaloid extracted from natural plants, exhibits effective anti-inflammatory, anti-tumor, and anti-oxidation activities. Here we re-ported that PAL alleviated LPS-induced acute lung injury and attenuated inflammatory cell infiltration especially neutrophils. Moreover, PAL also attenuated the production of TNF-alpha, CXCL-1, CXCL-2 and nitric oxide in bronchoalveolar lavage fluid. In addition, PAL remarkably reduced LPS-induced expression of TNF-alpha, CXCL-1 and CXCL-2 in bone marrow derived macrophages (BMDMs) and alveolar macrophages (AMs). Treatment with PAL inhibited the phosphorylation and interaction of TAK1/TAB1, which in turn attenuated the p38 MAPK and NF-KB signal pathways in BMDMs. Our results indicated that PAL ameliorated LPS-induced ALI by inhibiting macrophage activation through inhibiting NF-KB and p38 MAPK pathways, suggesting that PAL has anti -inflammation effect on ALI.

Automated summary

Palmatine (PAL) can alleviate acute lung injury (ALI) by inhibiting macrophage activation and attenuating the inflammatory response. PAL has inhibitory effects on the production of inflammatory mediators in cells and fluids. Additionally, PAL regulates macrophage function by inhibiting the activation of NF-KB and p38 MAPK signaling pathways.